• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 4. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

Introduction to 2-(pyrimidin-2-yl)butanedioic acid (CAS No: 2228659-74-1)

2-(pyrimidin-2-yl)butanedioic acid, identified by the Chemical Abstracts Service Number (CAS No) 2228659-74-1, is a significant compound in the realm of pharmaceutical and biochemical research. This heterocyclic organic compound features a butanedioic acid moiety linked to a pyrimidine ring, making it a versatile scaffold for the development of novel bioactive molecules. The structural integration of these functional groups imparts unique chemical and biological properties, rendering it a subject of considerable interest in medicinal chemistry.

The compound’s molecular structure consists of a four-carbon chain with carboxyl groups at both termini, connected to a pyrimidine ring at the second carbon position. This arrangement facilitates diverse interactions with biological targets, including enzymes and receptors. The pyrimidine moiety, a core component of many nucleoside analogs and anticancer agents, contributes to the molecule’s potential pharmacological activity. The butanedioic acid (or fumaric acid derivative) segment enhances solubility and metabolic stability, which are critical factors in drug design.

In recent years, 2-(pyrimidin-2-yl)butanedioic acid has garnered attention for its role as an intermediate in synthesizing pharmacologically relevant derivatives. Researchers have explored its utility in developing small-molecule inhibitors targeting various therapeutic pathways. For instance, modifications to the pyrimidine ring have led to compounds with antiviral and anti-inflammatory properties. The carboxyl groups provide sites for further functionalization, enabling the creation of prodrugs or conjugates that improve bioavailability and target specificity.

One of the most compelling aspects of this compound is its potential in oncology research. The pyrimidine scaffold is well-documented for its ability to interact with DNA and RNA, making it a valuable component in designing chemotherapeutic agents. Preclinical studies have indicated that derivatives of 2-(pyrimidin-2-yl)butanedioic acid may disrupt cancer cell proliferation by inhibiting key kinases or modulating transcription factor activity. These findings align with the broader trend in oncology toward developing precision medicines that exploit specific molecular targets.

The synthesis of 2-(pyrimidin-2-yl)butanedioic acid (CAS No: 2228659-74-1) involves multi-step organic reactions, typically starting from readily available precursors such as malonic acid derivatives and pyrimidine intermediates. Advanced synthetic techniques, including palladium-catalyzed cross-coupling reactions, have been employed to achieve high yields and purity. The optimization of these synthetic routes is crucial for large-scale production, ensuring that pharmaceutical-grade material is obtained for subsequent applications.

From a biochemical perspective, the compound’s dual functionality allows it to participate in multiple types of interactions within biological systems. The carboxyl groups can engage in hydrogen bonding or form ionic bridges with amino acids or other biomolecules, while the pyrimidine ring can stack with aromatic residues in proteins or bind to nucleobases in nucleic acids. This versatility makes it an attractive candidate for structure-based drug design, where understanding molecular interactions at the atomic level is paramount.

Recent advancements in computational chemistry have further enhanced the exploration of 2-(pyrimidin-2-yl)butanedioic acid derivatives. Molecular docking simulations and virtual screening have enabled researchers to predict binding affinities and identify promising candidates for experimental validation. These computational approaches complement traditional high-throughput screening methods, providing a more efficient pipeline for drug discovery. Moreover, machine learning models trained on large datasets of bioactive compounds have been used to predict new analogs with improved potency and selectivity.

The pharmacokinetic profile of 2-(pyrimidin-2-yl)butanedioic acid is another area of active investigation. Studies have focused on optimizing absorption, distribution, metabolism, excretion (ADME) properties to enhance therapeutic efficacy while minimizing side effects. For example, modifications such as esterification or amide bond formation can influence solubility and metabolic clearance rates. Understanding these parameters is essential for translating preclinical findings into clinical applications.

In conclusion, 2-(pyrimidin-2-yl)butanedioic acid (CAS No: 2228659-74-1) represents a promising scaffold in pharmaceutical research due to its structural versatility and potential biological activity. Its role as an intermediate in synthesizing novel therapeutic agents underscores its importance in drug development pipelines. As research continues to uncover new applications and refine synthetic methodologies, this compound is poised to make significant contributions to medicine and biotechnology.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)